Piśmiennictwo

1. Fuchs R, Guggenberger D, Neumann U. Nowotwory przewodu pokarmowego. Lublin: Czelej, 2012

2. Krzakowski M, Dziadziuszko R, Fijuth J. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Gdańsk: ViaMedica, 2011

3. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advances hepatocellular carcinoma. N Engl J Med 2008;359:378-90

4. Gliński B, Mucha-Małecka A, Jakubowicz J. Rola radioterapii w leczeniu chorych z pierwotnymi i przerzutowymi guzami wątroby. Współczesna Onkologia 2008;12:272-5

5. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008;26:657-64

6. Kilby W, Dooley JR, Kuduvalli G, et al. The CyberKnife Robotic Radiosurgery System In 2010. Technol Cancer Res Treat 2010;9:433-52

7. Dewas S, Dewas-Vautravers C, Serpent V, et al. Results and special considerations when treating elderly patients with CyberKnife: a review of 345 cases. Crit Rev Oncol Hematol 2011;79:308-14

8. Kwon JH, Bae SH, Kim JY, et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010;10:475

9. O’Connor JK, Trotter J, Davis GL, et al. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 2012;18:949-54

10. Vautravers-Dewas C, Dewas S, Bonodeau F, et al. Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? Int J. Radiation Oncology Biol Phys 2011;8:39-47

11. Dewas S, Bibault J-E, Mirabel X, et al. Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapy. Radiat Oncol 2012;7:166